Headlines about Neuralstem (NASDAQ:CUR) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Neuralstem earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.6361787149948 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Neuralstem (NASDAQ CUR) traded down $0.06 on Tuesday, reaching $1.12. The company had a trading volume of 244,109 shares, compared to its average volume of 344,530. Neuralstem has a 1 year low of $0.99 and a 1 year high of $6.60.

Neuralstem (NASDAQ:CUR) last released its earnings results on Tuesday, August 8th. The company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($9.49) by $9.10. Neuralstem had a negative return on equity of 321.78% and a negative net margin of 198,573.91%.

Separately, ValuEngine cut Neuralstem from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.watchlistnews.com/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-neuralstem-cur-share-price/1686428.html.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.